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The first overview of systemic adjuvant treatment for early
breast cancer by The Early Breast Cancer Triallists' Col-
laborative Group (EBCTCG) was published in 1990. It dem-
onstrated. over a 5 year period, a significant improvement in
mortality for women over the age of 50 when treated with
tamoxifen and for women under the age of 50 when treated
with chemotherapy.
The publication in 1992 of the second EBCTCG overview
provides us with reliable data over 10 years of follow-up
(Early Breast Cancer TInallists' Collaborative Group,
1992a,b). It has answered a number of important questions,
provided some unexpected results and raised a series of new
issues to be addressed by future research, particularly in
terms of the potential benefits to be realised by combinations
of systemic chemotherapy and hormonal therapies in women
of all ages.
The 1992 overview has confirmed the efficacy of
chemotherapy for women under the age of 50, and of tamox-
ifen for women over the age of 50. For women aged less than
50. the use of adjuvant combination chemotherapy reduces
the annual odds of recurrence by 37% with a standard
deviation of ± 5% (SD5) and the annual odds of death by
27% (SD6). For women over the age of 50, the use of
adjuvant tamoxifen reduces the annual odds of recurrence by
30% (SD2) and the annual odds of death by 19% (SD3).
Since the vast majority of women who develop recurrent
breast cancer ultimately die from the disease, it is anticipated
that. after sufficiently long periods of follow-up, the reduc-
tion seen in the annual odds of death will match that seen for
recurrence. To convert these figures into numbers which are
more easily understood. a reduction in the annual odds of
death of about 30% equates to approximately 12 extra
women alive at 10 years for every 100 women treated with
stage II breast cancer, and approximately six extra women
alive at 10 years for every 100 women treated with stage I
breast cancer. Although these improvements do not appear
large, they should be considered in the context of the millions
of women treated worldwide each decade for operable breast
cancer. Adjuvant treatment ofjust one million women could
well prevent, or substantially delay, an additional 100 000
deaths.
The first overview (Early Breast Cancer Triallists' Col-
laborative Group, 1990) suggested a limited role for hor-
Correspondence: TJ Perren
*P Barrett-Lee. Velindre Hospital. Cardiff; JM Bliss. Institute of
Cancer Research. Sutton; J Brown. Brunel University. Uxbridge.
Middlesex; AM Brunt. North Staffordshire Royal Infirmary. Stoke;
A Cull. Western General Hospital. Edinburgh; S Denton. St Bar-
tholomew's Hospital. London; H Earl. CRC Trials Umlt. Birmin-
gham. WD George. Western Infirmary. Glasgow: A Gould. Scottish
Cancer Therapy Network. Edinburgh; A Harnett. Beatson Oncology
Centre. Glasgow; M Mason. Velindre Hospital. Cardiff; J Mossman.
UKCCCR. London; M Richards. Guy's Hospital. London; J Yar-
nold. Royal Marsden Hospital. Sutton; R Collins (Observer) ICRF
Clinical Tnrals Unit. Oxford.
Received 15 June 1994; revised 15 February 1995; accepted 15 Feb-
ruary 1995
monal manipulation in women aged less than 50 with breast
cancer. Data from trials of adjuvant tamoxifen suggested a
significant reduction in the annual odds of recurrence, but no
significant reduction in mortality. Data with respect to
ovarian ablation were incomplete.
The 1992 overview has unexpectedly shown that ovarian
ablation used as adjuvant therapy in this group of women
results in a 30% (SD9) reduction in the annual odds of
recurrence and a 28% (SD9) reduction in the annual odds of
death. The magnitude of this effect shows no sign of
diminishing even after 15 years of follow-up.
More detailed analyses of the tamoxifen trials in women
aged less than 50 in the 1992 overview have also provided
some surprises with respect to duration of tamoxifen
administration. The previous interpretation of these analyses
was misleading. since patients treated with both tamoxifen
and chemotherapy had a shorter duration of tamoxifen
administration (mean 1.6 years) than those treated with
tamoxifen alone (mean 2.6 years). Thus. comparisons of
tamoxifen duration between trials were likely to have been
confounded by the use of chemotherapy. In the 1992 over-
view. unconfounded analyses of tamoxifen duration in 2216
women treated for a mean of 2.6 years have shown a reduc-
tion in the annual odds of recurrence of 277% (SD7) and in
the annual odds of death of 17% (SDIO). not dissimilar to
the results achieved for women over the age of 50. Indeed.
further breakdown of these data reveal that. when women
aged less than 50 are treated with tamoxifen for 2 years or
more, the reduction in the annual odds of recurrence is 43%
(SD 1), and in the annual odds of death is 27%
(SD17) - very similar to those figures described earlier for
chemotherapy in this age group. However, it should be noted
that because of relatively small numbers in these analyses the
confidence intervals are much wider than those in the
chemotherapy analyses. implying a degree of statistical ins-
tability to the results.
The first overview also suggested a limited role for
chemotherapy when given alone to women over the age of
50. for whom a significant reduction in the annual odds of
recurrence was demonstrated, but this did not translate into
a significant effect on mortality. The 1992 overview, however.
clearly shows that chemotherapy does in fact have a
sigificant effect in this age group. reducing the annual odds
of recurrence by 22% (SD4). and the annual odds of death
by 14% (SD5).
Thus, for women aged less than 50. there are three effective
treatments. namely chemotherapy. ovarian ablation and
tamoxifen. And for women over the age of 50 there are two
effective treatments, namely tamoxifen and chemotherapy.
What is not known with any accuracy at the present time is
what happens when these treatments are combined and
whether the benefits are additive. Data now available from
the 1992 overview. shown in Table I. suggest that, for women
aged less than 50. tamoxifen may be less effective when given
in combination with chemotherapy. in that the additional
reductions in the annual odds of recurrence and death from
the addition of tamoxifen were only 7% (SD4) and 3%
(SD5) respectively when compared with chemotherapy aloneAdjvanttheapy for operabe brast cancer
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Table I Estimates from the 1992 overviewofreductions in theannual oddsofrecurrenceand
death in tnrals testing combinations of chemotherapy (CT). ovanran suppression (OS) or
tamoxifen (Tam)
Percentage reduction
(s-d.) in annual odds of
Number of Recurrence or Deathfrom
Tipe of sYstemic therapy patients prior death anY cause
.4ge <50 years
(a)CT *sCT+OS 939 21 (9) 19(11)
(b) CT is CT + Tam (mean 1-6 vears) 6362 7 (4) 3 (5)
(c) Tam *s Tam + CT 386 32 (16) -6 (23)
.4ge 50 +-iears
(d) Tam *sTam+CT 3932 26 (5) 10 (7)
(e) CT *s CT+Tam 8148 28 (3) 20 (4)
Note that the indicated reductions in the annual odds of recurrence and death are in
addition to those reductions already achieved by the therapy in the control arm alone.
(Table Ib). However. these data are based on women receiv-
ing tamoxifen for a mean of only 1.6 years. The importance
of tamoxifen duration in this age group has been discussed
above. and currently it remains unknown whether this appar-
ent inefficacy simply represents an effect of inadequate
tamoxifen duration. Since chemotherapy is of proven benefit
in women aged less than 50. it might be expected that the
addition of chemotherapy to prolonged tamoxifen in this age
group would confer additional survival benefits. However.
only 386 patients worldwide have been included in such a
randomisation (Table Ic). These data do suggest a reduction
in the annual odds of recurrence. However, there have been
too few events to provide reliable statistical data, particularly
concerning surVival.
Adjuvant chemotherapy in premenopausal women fre-
quently leads to temporary. or permanent. amenorrhoea.
Amenorrhoea is known to occur more frequently in the older
pre- or perimenopausal women (Richards et al.. 1990). This
has led to the suggestion that adjuvant chemotherapy may
work via an endocrine mechanism: this is. however. unlikely
to be fully accurate since adjuvant chemotherapy is now
known to have a clear effect in post-menopausal women.
Furthermore, data from 939 patients aged less than 50, who
were receiving chemotherapy and also randomised to ovarian
suppression. showed a further reduction in the annual risks
of recurrence and death of 21% (SD9) and 19% (SDll)
respectively, a result that did not quite achieve statistical
significance (Table Ia).
There are. however. no data available from randomised
trials comparing chemotherapy in combination with ovarian
suppression with ovarian suppression alone. Equally. there
are also no data on the effects of adjuvant ovarian suppres-
sion in patients already receiving tamoxifen. Given that the
use of tamoxifen in premenopausal women results in an
increase in circulating oestradiol levels, it is feasible that
there may be an additional therapeutic benefit from the use
of ovarian suppression in such patients. This hypothesis is
supported by data in metastatic disease showing responses to
tamoxifen in patients who have developed progressive disease
following ovarian ablation, and vice versa (Ingle et al.. 1986).
In order to resolve these issues, a randomised clinical trial
is clearly needed but, as has been demonstrated by the 1992
overview itself, the effects achieved with adjuvant therapies
are relatively small and require large patient numbers in
order to demonstrate them reliably. The United Kingdom
Central Coordinating Committee for Cancer Research
(UKCCCR) adjuvant breast cancer (ABC) trial, which was
launched in 1993. is a simple and pragmatic trial designed to
recruit several thousand patients over a short period of time.
It is estimated that in order to demonstrate a 5% difference
in survival between arms of the study around 2000 patients
will be required for each comparison. The trial has the
backing of the Faculty of Clinical Oncology at the Royal
College of Radiologists. the Scottish Cancer Trials Breast
Group. the West Midlands Breast Group and the Yorkshire
Breast Cancer Group. It also has the support of a large
number of non-affiliated oncologists entering patients directly
through the ABC Trials Office. Some patients have already
been entered from overseas and further international col-
laboration is anticipated. In the UK around 15 000 new cases
of breast cancer are diagnosed in women aged less than 70
each year. and with the level of support already demon-
strated from the UK and overseas recruitment to the trial
should be completed in the next 3-4 years. For those treat-
ment comparisons to which too few patients are randomised
to provide definitive evidence on survival, the data generated
will make a substantial contribution to future overviews.
Within the trial all patients are treated with prolonged
adjuvant tamoxifen. Currently. treatment is recommended for
a period of 5 years, but the trial design allows clinicians also
to enter their patients into trials of tamoxifen duration
should they feel this is appropriate.
The recommendation that all pre- and perimenopausal
women should receive tamoxifen is based upon the apparent
efficacy of this drug when given in a prolonged fashion to
premenopausal women as well as its safety profile. It is also
based on pragmatic principles, since many UK clinicians are
already using tamoxifen as standard therapy in this group of
women.
For pre- or perimenopausal women the clinician decides
for each individual patient whether he or she would recom-
mend therapy with either chemotherapy or ovarian suppres-
sion in addition to the standard therapy of tamoxifen alone.
For premenopausal patients. if uncertainty exists concerning
either of these treatments. the clinician is free to offer ran-
domisation to that option. Thus. after discussion and con-
sent. patients may be randomised between chemotherapy and
no chemotherapy or between ovarian suppression and no
ovarian suppression, or may enter into both randomisations.
For women over the age of 50. the data from the 1992
overview already suggest that tamoxifen and chemotherapy
have a largely independent action and that their effect may
well be additive (Table Id and e). However, it is as yet
uncertain whether the additional toxicity from such com-
bined modality therapy will be worthwhile to individual
patients. This is illustrated by the fact that most post-
menopausal women with breast cancer in the UK are not
currently offered chemotherapy. This question is addressed in
the ABC trial through a randomisation between tamoxifen
alone and tamoxifen plus chemotherapy.
While the ABC trial is designed to be simple and to keep
paperwork to a minimum, it is recognised that the additional
discussion required in order to obtain patients' consent to
randomisation will significantly increase the workload of par-
ticipating clinicians. In recognition of this, preliminary fun-
ding of £30 000 has been granted by the Medical Research
Council to provide participants with a sum of money. on a
per capita basis. which can be used to pay for staff to
support the running of the trial within individual centres.
Examination of the recruitment data shows that the tnral is
now clearly viable, and by the end of 1994 855 patients had
been recruited to the ABC tnral. 545 from the UK and 310
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from overseas. As a result of successful recruitment a
definitive grant is now being sought through the UKCCCR
to support the further running of the trial over the next few
years.
The success of the ABC trial depends not only on
dedicated clinicians, but also on a steady supply of patients
who are prepared to give consent to be randomised into the
study. To this end the trial has been developed in consulta-
tion with organisations representing the interests of patients,
including BACUP. Breast Cancer Care and the UK Breast
Care Nursing Society. It will also be important to widen the
public debate concerning participation of patients in clinical
trials. Currently patients are often taken aback when app-
roached concerning a clinical trial: ideally they, should expect
to be offered entry into clinical trials. By heightening public
awareness and broadening discussion of these items, the ABC
trial can make a contribution to achieving this aim.
The advisory group on health technologies has already
recognised the importance of well-designed randomised trials
to the research and development strategy of the National
Health Service.'A trial such as the ABC trial has, on the
basis of previous research, identified a possible improvement
in the treatment of a major health problem. and sets out to
test this in a large number of patients. Issues such as quality
of life will be incorporated into the trial, as an additional and
voluntary module to be conducted in certain centres, as it is
clearly important to be able to determine whether the addi-
tional toxicities resulting from combined modality treatments
are worthwhile in terms of improved outcome for patients.
Of particular concern are the long-term toxicities that may
result from ovarian ablation in the younger premenopausal
women, as well as the shorter term, but nevertheless poten-
tially substantial. toxicities that may result from the addition
of chemotherapy to tamoxifen in post-menopausal women.
The results of the ABC trial will ultimately be analysed with
respect to their impact and cost, allowing calculation of
statistics such as number of women-years of life saved, the
added costs of treatment and cost savings of a cured patient.
A study of the size of the ABC trial will also facilitate the
development of parallel studies to investigate aspects of the
biology of breast cancer. Of particular interest is the further
investigation and refinement of markers that may predict for
chemotherapy or endocrine responsiveness. In premenopausal
women there is already a suggestion from a trial that com-
pared adjuvant combination chemotherapy with adjuvant
ovarian ablation that the benefits of ovarian ablation were
mainly seen in patients with hormone receptor-positive
tumours and the benefits of chemotherapy mainly in patients
with hormone receptor-negative tumours (Scottish Cancer
Trials Breast Group and ICRF Breast Unit. Guys Hospital.
London. 1994). Other trials have suggested that CMF-type
adjuvant chemotherapy may be most effective in patients
with tumours negative for the c-erbB-2 oncogene (Allred et
al.. 1992; Gusterson et al.. 1992). while a trial of dose inten-
sity incorporating adjuvant anthracycine based chemo-
therapy has suggested that dose-intensive anthracycline
chemotherapy has its main effect in patients with tumours
positive for the c-erbB-2 oncogene (Muss et al., 1994). How-
ever. all of these studies are relatively small or derived from
subgroups of larger studies and require confirmation. Well-
conducted biological studies run alongside a trial of the size
of the ABC study will be able to contribute significantly to
this research. Ultimately the goal must be to identify reliable
markers that will allow specific treatments, or combinations
of treatments. to be targeted to the individuals most likely to
benefit from them. If this can be achieved it will also be
possible to spare patients from receiving treatments they do
not require. as well as to identify patients not well served by
the current generation of adjuvant therapies who will become
candidates for experimental therapies. A side-effect of this
activity will be the generation of a sizeable well-documented
tumour bank which will be available for testing the
significance of new markers identified by ongoing fundamen-
tal molecular biological and genetic research.
Any clinician currently treating patients with operable
breast cancer who is not already entering patients into
clinical trials is urged to join the ABC trial. It is only
through participation in such studies as this that we will be
able further to define optimal treatments for individual
patients.
For further information and in order to discover who is
coordinating the ABC trial in your region contact Lindsay
Johnson by telephone. 0181 643 8901 extension 4188, or fax,
0181 770 7876.
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